Reducing Edema After intraCerebral Hemorrhage

Summary

The REACH trial is a prospective multicenter double-blind randomized placebo-controlled trial with blinded end-point adjudication. Participants are randomized (1:1) to receive either sodium aescinate or matching placebo (0.9% saline). The primary outcome is the absolute volume of PHE evaluated based on brain CT image on day 14 after ICH.

Timeline

Start

2022-03-15

Primary completion

2024-12-31

Completion

2025-03-31

Drugs

Indications